Nutra Pharma Corp. (NPHC) CEO Featured in Exclusive QualityStocks Interview
December 16, 2015
SCOTTSDALE, AZ--(Marketwired - Dec 16, 2015) - QualityStocks today announces the availability of a new audio interview with Rik Deitsch, CEO of Nutra Pharma Corp. (OTCQB: NPHC), a biotech company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The interview can be heard at http://www.QualityStocks.net/interview-nphc.php.
Nutra Pharma is developing a broad product platform for numerous indications, and it currently has 21 patents in its intellectual property portfolio. The QualityStocks interview begins with Deitsch describing Nutra Pharma's business model and three key patents: one for autoimmune disease, one for antiviral therapeutics, and one for the treatment of pain. Nutra Pharma also has launched a line of over-the-counter (OTC) pain drugs (Nyloxin, for humans, and Pet Pain-Away, for dogs and cats), which financially buoy the research and development of the company's potential blockbuster drugs.
"The sales of these OTC drugs produce revenue that mitigates the risk to investors and actually pays for the clinical research as we move the products forward," Deitsch explains.
Before highlighting other individuals on the company's management team, Deitsch, a seasoned biochemist, adjunct professor and author, describes his extensive professional background, which includes 25 years researching drugs derived from venomous animals, and employment with the world's largest manufacturer of dietary supplements, for which he formulated more than 50 dietary supplements and conducted more than 50 clinical studies.
The topic then turns to several of Nutra Pharma's historical milestones, its strategies to increase domestic and international reach, and how it transitioned into its current line of operations. One of Nutra Pharma's largest achievements to-date, says Deitsch, is obtaining Orphan Drug Status from the U.S. FDA for RPI-78M for pediatric multiple sclerosis (MS).
"We went back and forth with the FDA for several weeks, but it only took about five weeks from the point where we applied for Orphan Drug Status to actually getting the Orphan Status designation, which is huge," he says. "It really means the FDA saw the value that we had in our drug."
Deitsch next describes the advantages of this corporate achievement, how it prepares the company to move into a larger market, and how it differs from currently available drugs.
"With our drug ... we stop the hyper immune response that causes multiple sclerosis. So from the day you start taking the drug, what we've seen in our clinical research is that your disease progression stops and over time your symptoms improve. So this is a game-changer when it comes to treating any auto-immune disease, but certainly when it comes to treating multiple sclerosis. We really believe that we're going to prove this in our clinical studies and then we'll seek a licensed partner," he says.
In the near future, Nutra Pharma plans on commencing and completing phase II clinical studies of RPI-78M and building a strong domestic sales force to increase sales and availability of its Nyloxin and Pet Pain-Away Products.
"I think that as we get this message out there we're going to see a huge increase in sales that of course is not only going to help bring the company to the next level, it's going to help us create more and more products for our platform that we're going to be able to license to big pharma in the next 12-18 months," concludes Deitsch.
About Nutra Pharma Corp.
Nutra Pharma Corp. operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. Additionally, the company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. For more information visit the company's website at www.NutraPharma.com.
Small Cap Stock Newsletter QualityStocks is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one free Daily Newsletter Report. QualityStocks also utilizes social media and networking to maintain constant communication with its rapidly growing audience. To date, QualityStocks has more than one million users following various social networking accounts.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
The QualityStocks Blog keeps investors up to date on everything related to the Small-Cap and Micro-Cap markets. Alternative fuels and power sources, entertainment media, telecommunications, delivery services, healthcare, and retail are all covered on a regular basis. By visiting our blog, investors also discover emerging companies that they otherwise would not have heard about. To date, more than 20,000 articles have been published via the QualityStocks Blog.
With all of the stock picks and recommendations available today in the investment world, selecting and deciding on the right stocks can be tedious and time consuming. At QualityStocks, we collate hundreds of investment newsletters into The ONE and ONLY "The QualityStocks Daily," featuring a summary format in which you can view the latest stock picks EVERYDAY.
You can SIGN UP NOW http://Signup.QualityStocks.net
QualityStocks Scottsdale, Arizona www.QualityStocks.com 480.374.1336 editor@QualityStocks.net
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.